ENTPD1 and synovial sarcoma: The use of monoclonal antibodies and small molecule inhibitors targeting CD39, CD73, and CD38, or with immune checkpoint inhibitors, holds promise as a therapeutic option for SS, providing new directions and guidance for the treatment of patients.